Sygnis Pharma AG Konv - Stockquote Aktien & Wertpapierkurse
powered by GOYAX

Ad Hoc Releases

2011/2012

Dec 15, 2011
SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke
Aug 10, 2011
SYGNIS Pharma AG successfully completes capital increase
Jul 20, 2011
SYGNIS Pharma AG decides on increase in share capital
Jun 15, 2011
SYGNIS Pharma AG secures further financial resources with shareholder loan

2010/2011

Oct 29, 2010
SYGNIS Pharma AG announces strategic restructuring
Oct 28, 2010
Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG

2009/2010

Oct 19, 2009
SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement with Yorkville

2008/2009

Nov 14, 2008
SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG
Oct 15, 2008
SYGNIS Pharma AG Approves Capital Increase
Jun 08, 2008
SYGNIS announces agreement on acquisition of Amnestix Inc.

2007/2008

Jul 22, 2007
SYGNIS announces successful completion of the clinical IIa study for AX200 in stroke (AXIS)

You are here : SYGNIS Pharma AG > Investor Relations > Ad Hoc
Imprint Disclaimer © 2012 SYGNIS AG